// App-Quantinova.ai

102 : Assessing reasons for patients switching back from biosimilar etanercept therapy to originator product

Researchers

Presenter

  • Chanaka Dahanayake

Principal Investigators

  • Kavina Shah

  • Ahmad Al-Abdulla

  • Maresa Carulli

Medical Centers

  • Ophthalmology, Imperial College Healthcare NHS Trust, London, UNITED KINGDOM

Locations

  • United Kingdom

Companies

  • N/A

Study Components

Therapeutic Area

  • Autoimmune (AI)

Disease

  • Rheumatoid arthritis

Biomarkers

  • N/A

Drug/Treatment

  • Etanercept

  • CHS-0214

  • Etanercept biosimilar

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved